Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
- Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys
- Data published in the American Journal of Transplantation and to be presented as a poster at the Cutting Edge of Transplantation (CEoT) Summit, Scottsdale, Arizona, 26–28 February 2026
- Regulatory clearance granted by both UK MHRA and Health Canada for a Phase 1 clinical trial of SYN002, with Canadian study to be conducted independently by Dr. Atul Humar at UHN, Toronto
COPENHAGEN (February 25, 2026) – Synklino A/S, a Danish biotechnology company pioneering transformative therapies to improve kidney transplantation outcomes through better CMV prevention, today announces the publication of a preclinical study in the American Journal of Transplantation. The study titled Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin is available on open access here.
